Linaclotide Attenuates Visceral Organ Crosstalk: Role of Guanylate Cyclase-C Activation in Reversing Bladder-Colon Cross-Sensitization.

Autor:	Mohammadi EN; Oklahoma Center for Neuroscience (E.N.M., C.O.L., B.G.-V.M.), Department of Physiology (B.G.-V.M.), and Veterans Affairs Medical Center (B.G.-V.M.), University of Oklahoma Health Science Center, Oklahoma City, Oklahoma; and Ironwood Pharmaceuticals, Cambridge, Massachusetts (A.S.-S., P.G., C.K., C.H., G.H.)., Ligon CO; Oklahoma Center for Neuroscience (E.N.M., C.O.L., B.G.-V.M.), Department of Physiology (B.G.-V.M.), and Veterans Affairs Medical Center (B.G.-V.M.), University of Oklahoma Health Science Center, Oklahoma City, Oklahoma; and Ironwood Pharmaceuticals, Cambridge, Massachusetts (A.S.-S., P.G., C.K., C.H., G.H.)., Silos-Santiago A; Oklahoma Center for Neuroscience (E.N.M., C.O.L., B.G.-V.M.), Department of Physiology (B.G.-V.M.), and Veterans Affairs Medical Center (B.G.-V.M.), University of Oklahoma Health Science Center, Oklahoma City, Oklahoma; and Ironwood Pharmaceuticals, Cambridge, Massachusetts (A.S.-S., P.G., C.K., C.H., G.H.)., Ge P; Oklahoma Center for Neuroscience (E.N.M., C.O.L., B.G.-V.M.), Department of Physiology (B.G.-V.M.), and Veterans Affairs Medical Center (B.G.-V.M.), University of Oklahoma Health Science Center, Oklahoma City, Oklahoma; and Ironwood Pharmaceuticals, Cambridge, Massachusetts (A.S.-S., P.G., C.K., C.H., G.H.)., Kurtz C; Oklahoma Center for Neuroscience (E.N.M., C.O.L., B.G.-V.M.), Department of Physiology (B.G.-V.M.), and Veterans Affairs Medical Center (B.G.-V.M.), University of Oklahoma Health Science Center, Oklahoma City, Oklahoma; and Ironwood Pharmaceuticals, Cambridge, Massachusetts (A.S.-S., P.G., C.K., C.H., G.H.)., Higgins C; Oklahoma Center for Neuroscience (E.N.M., C.O.L., B.G.-V.M.), Department of Physiology (B.G.-V.M.), and Veterans Affairs Medical Center (B.G.-V.M.), University of Oklahoma Health Science Center, Oklahoma City, Oklahoma; and Ironwood Pharmaceuticals, Cambridge, Massachusetts (A.S.-S., P.G., C.K., C.H., G.H.)., Hannig G; Oklahoma Center for Neuroscience (E.N.M., C.O.L., B.G.-V.M.), Department of Physiology (B.G.-V.M.), and Veterans Affairs Medical Center (B.G.-V.M.), University of Oklahoma Health Science Center, Oklahoma City, Oklahoma; and Ironwood Pharmaceuticals, Cambridge, Massachusetts (A.S.-S., P.G., C.K., C.H., G.H.)., Greenwood-Van Meerveld B; Oklahoma Center for Neuroscience (E.N.M., C.O.L., B.G.-V.M.), Department of Physiology (B.G.-V.M.), and Veterans Affairs Medical Center (B.G.-V.M.), University of Oklahoma Health Science Center, Oklahoma City, Oklahoma; and Ironwood Pharmaceuticals, Cambridge, Massachusetts (A.S.-S., P.G., C.K., C.H., G.H.) beverley-greenwood@ouhsc.edu.
Jazyk:	angličtina
Zdroj:	The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2018 Aug; Vol. 366 (2), pp. 274-281. Date of Electronic Publication: 2018 May 21.
DOI:	10.1124/jpet.118.248567
Abstrakt:	Bladder pain syndrome (BPS) is poorly understood; however, there is a female predominance and comorbidity with irritable bowel syndrome (IBS). Here we test the hypothesis that linaclotide, a guanylate cyclase-C (GC-C) agonist approved for the treatment of IBS with constipation (IBS-C), may represent a novel therapeutic for BPS acting through a mechanism involving an inhibition of visceral organ cross-sensitization. We showed previously that infusion of dilute protamine sulfate (PS) into the bladder increased sensitivity and permeability in the bladder and colon. PS was infused into the bladder of female rats; sensitivity was assessed via application of von Frey filaments applied to the suprapubic area and the frequency of withdrawal responses was recorded. Colonic sensitivity was measured via visceromotor behavioral response to graded pressures of colorectal distension (CRD). Permeability was measured in vitro via transepithelial electrical resistance (TEER) and conductance (G). Linaclotide (3 µ g/kg, p.o.) or vehicle was administered daily for 7 days prior to experiments. Rats treated with PS bladder infusion exhibited visceral hyperalgesia, as shown by a significantly higher response frequency to individual von Frey filaments and increased behavioral responses to CRD. Linaclotide attenuated bladder and colonic hyperalgesia to control levels. PS infusion into the bladder increased bladder and colon permeability measured as a decrease in TEER and increased G. Linaclotide significantly inhibited PS-induced colonic hyperpermeability while having no effect on bladder hyperpermeability. Our findings suggest a novel treatment paradigm for GC-C agonism in IBS-C and BPS mediated through a mechanism involving visceral organ crosstalk. (U.S. Government work not protected by U.S. copyright.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu